-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Upgrades Belite Bio to Outperform, Raises Price Target to $194

Benzinga·12/02/2025 15:06:00
Listen to the news
Mizuho analyst Graig Suvannavejh upgrades Belite Bio (NASDAQ:BLTE) from Neutral to Outperform and raises the price target from $105 to $194.